The FDA has approved once-daily oral upadacitinib for the treatment of adults with active ankylosing spondylitis who are intolerant, or have had an inadequate response, to one or more TNF inhibitors.
“Ankylosing spondylitis is a debilitating disease that often affects younger adults and, over time, can result in lasting structural damage that can take an emotional toll on a patient’s life,” Thomas Hudson, MD, senior vice president of research and development, and chief scientific officer, for AbbVie, said in a company press release. “This latest approval demonstrates another